HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Lymphoma

Interventions

DRUG: HMPL-523
DRUG: Itraconazole
DRUG: Rifampin

Sponsor

Hutchmed